Home Healthcare Cough Suppressant Drugs Market: Frequent Approvals and Launch of New Development
Cough Suppressant Drugs Market: Frequent Approvals and Launch of New Development

Cough Suppressant Drugs Market: Frequent Approvals and Launch of New Development

Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant drugs market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.

Read Press Release on Cough Suppressant Drugs Market: https://www.coherentmarketinsights.com/press-release/cough-suppressant-drugs-market-to-surpass-us-15188-mn-threshold-by-2026-1248 

Various key players in the market are conducting research and are evaluating safety and efficacy of various drugs for the treatment of cough. Such initiatives taken by companies is expected to lead to the development of new cough suppressant drugs.

For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.

Moreover, high prevalence of cough is expected to increase the demand for cough suppressant drugs, thereby driving the market growth. For instance, according to the study published by the National Center for Biotechnology Information in 2013, cough is a very common condition and around 12% of the people in Britain experience chronic cough, daily or weekly.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2427 

For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.

In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment drugs. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.

Browse Full Report: https://www.coherentmarketinsights.com/market-insight/cough-suppressant-drugs-market-2427 

Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]


Mohit Joshi
All Posts